This new accolade joins our previous recognitions: - 🏆 2021: Prix de la Région Pays de la Loire at Start West. - 🏆 2022: Award for job creation at Startups & Innovation Day Each award reminds us of all the progress we've made since our launch in 2021.

Last week, our CEO Frédéric Pette proudly received a trophy from @bpifrance, marking BioMAdvanced Diagnostics' selection to join the prestigious Club Excellence. #Atlanpole #AtlanpoleBiotherapies #LaFrenchCare #medtech

🚀 [Q1 2024 – recap] Our first 3 months of 2024 have already been marked by several key milestones, enabling us to stay confident about our current scheduled roadmap and to prepare for a global launch. Details : biomadvanced-diagnostics.com… #MedTech #LaFrenchCare

Wondering how we're able to process our clinical trials at such a rapid pace? The secret lies in Bio-collections (or Biobanks). These collections of samples (blood, biopsies, etc.) and clinical data, gathered from patients recruited without bias. #MedTech

“BioMAdvanced Diagnostics” and its logo have been successfully registered as Trademarks in the United States of America. Another step in our journey towards delivering great diagnostics solutions to transplanted patients and their clinicians around the world! #medtech #nantes

Why does this matter ? Companies involved in the development and manufacturing of Medical Devices are REQUIRED to have a Certified Quality System in accordance with the ISO 13485 standard.

[Milestone] BiomAdvanced Diagnostics is ISO 13485 certified by BSI under certificate number MD 775018. #ISO13485 #RegulatoryAffairs #MedTech

These tests were conducted independently on two separate days under the supervision of our team. ▶▶▶We are pleased to announce that the product has met all of our expectations. (5/5)

📌In pursuit of this objective, two Medical Biology Engineers from a leading French University Hospital biology lab visited our own molecular biology lab. Without prior knowledge of the product, they conducted tests solely relying on the provided instructions for use. (4/5)

This phase is aiming at verifying/validating the user interfaces while taking into account the human factor (essentially checking the ease of use and the safety/risk management). (3/5)

As our product development progresses, we are currently immersed in the summative usability assessment of our kidney IVD test, encompassing both the kit and software components. (2/5)